US 12,139,511 B2Granted

Influenza virus hemagglutinin mutants

AssigneeAramis Biotechnologies Inc.

InventorsPierre-Olivier Lavoie, Aurelien Lorin, Alain Doucet, Marc-Andre D'Aoust, Manon Couture

Life of this patent

Estimating the term…

Loading patent…

Abstract

Production of modified influenza viral proteins in plants is described. More specifically, producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA) is described. The HA protein may comprise an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acids encoding the modified HA protein. Furthermore, methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

Claims4

Dependent claims

A nucleic acid comprising a nucleotide sequence encoding a modified influenza H3 hemagglutinin (HA) protein, the HA protein comprising an amino acid sequence of a wildtype influenza H3 HA protein and comprising at least one amino acid substitution, said at least one amino acid substitution consisting of an amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO:

92 and optionally one or more amino acid substitution corresponding to positions 384, 392 and/or 431 of reference sequence SEQ ID NO:
92,
wherein:
the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO:
92 is to an alanine or a conserved substitution of alanine;
the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO:
92 is to a valine or a conserved substitution of valine;
the amino acid substitution corresponding to position 392 of reference sequence SEQ ID NO:
92 is to an aspartic acid or a conserved substitution of aspartic acid;
and
the amino acid substitution corresponding to position 431 of reference sequence SEQ ID NO:
92 is to a methionine or a conserved substitution of methionine.

9 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/255,520Filed 27 Jun 2019 · us provisional application
Priority: 27 Jun 2018
Published: US 2021/0371472 A12 Dec 2021
Granted: 12 Nov 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification25 codes

C12P 21/02
Preparation of peptides or proteins: having a known sequence of two or more amino acids, e.g. glutathione
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 39/145
Viral antigens: orthomyxoviridae, e.g. influenza virus
A61P 31/16
For RNA viruses: for influenza or rhinoviruses